Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations

v3.4.0.3
Consolidated Statements of Operations - USD ($)
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Revenue:    
Lymphoseek sales revenue $ 3,782,680 $ 1,835,422
Lymphoseek license revenue 254,050 83,333
Grant and other revenue 685,825 189,701
Total revenue 4,722,555 2,108,456
Cost of goods sold 534,929 449,057
Gross profit 4,187,626 1,659,399
Operating expenses:    
Research and development 2,659,520 3,981,288
Selling, general and administrative 4,096,660 5,494,168
Total operating expenses 6,756,180 9,475,456
Loss from operations (2,568,554) (7,816,057)
Other income (expense):    
Interest expense, net (2,193,523) (966,576)
Equity in loss of R-NAV, LLC (12,239) (262,227)
Change in fair value of financial instruments 1,125,359 1,727,103
Other, net (37,292) 26,532
Total other income (expense), net (1,117,695) 524,832
Net loss (3,686,249) (7,291,225)
Less loss attributable to noncontrolling interest (241) (100)
Deemed dividend on beneficial conversion feature of MT Preferred Stock   (46,000)
Net loss attributable to common stockholders $ (3,686,008) $ (7,337,125)
Loss per common share (basic and diluted) $ (0.02) $ (0.05)
Weighted average shares outstanding (basic and diluted) 155,308,094 149,794,331